The In-vitro pH-Dissolution Dependence and In-vivo Bioavailability of Frusemide-PVP Solid Dispersions
- 1 February 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 41 (2) , 73-78
- https://doi.org/10.1111/j.2042-7158.1989.tb06396.x
Abstract
The dependence of the dissolution rate on the pH of the buffered medium, using constant surface area discs, has been examined for crystalline frusemide, a semi-crystalline frusemide-polyvinylpyrrolidone (PVP) solid dispersion and an X-ray amorphous frusemide-PVP dispersion. The marked changes observed in the pH-dissolution profiles indicate that differing dissolution mechanisms operate in the amorphous regions. This conclusion was further supported by the comparison of pH-dissolution and pH-equilibrium solubility profiles that suggested a supersaturation effect to be the relevant term in describing the dissolution enhancing effects of amorphous regions. A marked dissolution enhancement, relative to crystalline frusemide, was shown by the X-ray amorphous solid dispersion in weakly acidic solutions. A similar effect was observed in the dissolution characteristics of gelatin capsule formulations in simulated gastric and intestinal media. In a human bioavailability study, the X-ray amorphous frusemide-PVP solid dispersion exhibited a significant reduction in the time for maximum effect in comparison to crystalline frusemide and a semi-crystalline solid dispersion. This effect, demonstrated by the primary end organ response in seven healthy subjects, concurred with the in-vitro prediction of dissolution enhancement in weakly acidic media.This publication has 14 references indexed in Scilit:
- Mechanisms of dissolution of frusemide/PVP solid dispersionsInternational Journal of Pharmaceutics, 1987
- Factors Involved in Quantitative X-Ray Analysis of Solid DispersionsJournal of Pharmacy and Pharmacology, 1985
- An in-vivo - in-vitro correlation for the bioavailability of frusemide tabletsJournal of Pharmacy and Pharmacology, 1984
- Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteersEuropean Journal of Clinical Pharmacology, 1983
- Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemideEuropean Journal of Clinical Pharmacology, 1981
- Pharmacodynamic analysis of the furosemide-probenecid interaction in manKidney International, 1979
- Clinical Pharmacokinetics of FrusemideClinical Pharmacokinetics, 1979
- Determinants of response to frusemide in normal subjects.British Journal of Clinical Pharmacology, 1977
- Pharmaceutical Applications of Solid Dispersion SystemsJournal of Pharmaceutical Sciences, 1971
- Dissolution Rates of High Energy Polyvinylpyrrolidone (PVP)-Sulfathiazole CoprecipitatesJournal of Pharmaceutical Sciences, 1969